Dow Jones
37.775,38 +22,07 (+0,06%) Nasdaq
15.601,50 -81,87 (-0,52%) Nikkei 225
38.079,70 +117,90 (+0,31%) EUR/USD
1,0646 0,0000 (-0,00%) Bitcoin EUR
59.632,11 +2.040,14 (+3,54%) CMC Crypto 200
1.312,09 +426,56 (+48,15%)
ADC Therapeutics SA (ADCT)
Dopo ore:
| Chiusura precedente | 4,9600 |
| Aperto | 4,9500 |
| Denaro | 4,7100 x 800 |
| Lettera | 5,0000 x 800 |
| Min-Max giorno | 4,7200 - 4,9450 |
| Intervallo di 52 settimane | 0,3600 - 6,0400 |
| Volume | |
| Media Volume | 755.116 |
| Capitalizzazione | 392,841M |
| Beta (5 anni mensile) | 1,74 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -2,9400 |
| Prossima data utili | 07 mag 2024 - 12 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 10,20 |
GlobeNewswireMyricx Expands its ADC Expertise with the Appointment of Francesca Zammarchi as CSO
LONDON, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of selectively cytotoxic payloads for antibody-drug conjugates (ADCs), today announces the appointment of Francesca Zammarchi, Ph.D., as Chief Scientific Officer (CSO). Dr. Zammarchi joins Myricx as it accelerates the development of its pipeline of ADCs based on its first-in-class N-myristoyltransferase inhibitor (NMTi) payload platform. She
GlobeNewswireADC Therapeutics to Participate in September Investor Conferences
LAUSANNE, Switzerland, Sept. 05, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in two investor conferences in September. Details of the events are as follows: Morgan Stanley Global Healthcare Conference - fireside chat on Monday, September 11th from 2:15 p.m. – 2:45 p.m. ETCantor Global Healthcare Conference - fireside chat on Wednesday, September 27th from 4:45 p.m. – 5:15 p.m. ET Live webcasts of the fires
- GlobeNewswire
ADC Therapeutics Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023)
LOTIS-5: Updated safety run-in results from Phase 3 trial demonstrate 80% ORR, 50% CR rate and median DoR of 8 months with no new safety signals LOTIS-7: Study design of trial evaluating ZYNLONTA® in patients with r/r non-Hodgkin lymphoma to be highlighted in poster; actively enrolling patients in bispecific combination arms LAUSANNE, Switzerland, Aug. 30, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that two ZYNLONTA® (loncastuximab tesirine-lpyl) abstracts have bee
